|Bid||2.2700 x 900|
|Ask||2.2800 x 1400|
|Day's Range||2.2550 - 2.3599|
|52 Week Range||1.8800 - 6.1400|
|Beta (5Y Monthly)||1.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 15, 2023 - May 19, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Aug 28, 1996|
|1y Target Est||14.50|
VIENNA, Va., March 08, 2023--CEL-SCI’s Multikine Phase 3 cancer study shows 43% survival extension.
VIENNA, Va., March 03, 2023--CEL-SCI to present new Phase 3 data at European Congress on Head & Neck Oncology.
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT First Quarter Fiscal Year 2023 Update CEL-SCI Corporation (NYSE:CVM) reported first quarter fiscal year 2023 results on February 15, 2023 and filed its Form 10-Q with the SEC. The company has continued to compile the clinical documentation necessary to support a Biologic License Application (BLA), which will be submitted in